Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.62 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
| ▸ | BAD | Q92934 | 1/20 | 0.40 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.40 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6085748 | 0.98 | MGAM (0.60) | MGAMHCAR2EGLN1LDHAPSMD14 | |
| SCHEMBL4158038 | 0.86 | MGAM (0.62) | MGAMHCAR2EGLN1LDHAPSMD14 | |
| SCHEMBL10465639 | 0.85 | MGAM (0.70) | MGAMPSMD14MAPTPDGFRBPDGFRA | |
| SCHEMBL3868878 | 0.85 | HPGDS (0.50) | MGAMPSMD14MAPTMAPK1TNIK | |
| Hydrochloric Acid SCHEMBL6086242 | 0.85 | MGAM (0.60) | MGAMHCAR2EGLN1LDHAPSMD14 | |
| SCHEMBL12686640 | 0.85 | MGAM (0.44) | MGAMMAPTMAPK1KDM4ETSHR | |
| SCHEMBL15517731 | 0.81 | HTT (0.52) | PSMD14MAPTMAPK1KDM4EALDH1A1 | |
| SCHEMBL61876 | 0.81 | MGAM (0.64) | MGAMPSMD14MAP4K4PDGFRBPDGFRA | |
| SCHEMBL30447871 | 0.80 | GRM1 (0.45) | MGAMLMNA | |
| SCHEMBL20023713 | 0.80 | GRM1 (0.45) | MGAMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3528813-B1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ABS DEV 1 INC (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20240391925-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC (US) | 2024-11-28 | — | — | US | disclosed |
| US-12077543-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2024-09-03 | — | — | US | disclosed |
| CN-116854693-A | P2X 3 And/or P2X 2/3 Compounds and methods | 阿沙纳生物科学公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-109996546-B | P2X 3 And/or P2X 2/3 Compounds and methods | 阿沙纳生物科学公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20220227774-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2022-07-21 | — | — | US | disclosed |
| US-11339169-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339169-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2022-05-24 | — | — | US | disclosed |
| US-20200190096-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2020-06-18 | — | — | US | disclosed |
| US-20200190096-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2020-06-18 | — | — | US | disclosed |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | CODD ELLEN | 2008-12-04 | — | — | US | disclosed |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | CODD ELLEN | 2008-12-04 | — | — | US | disclosed |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | CODD ELLEN | 2008-12-04 | — | — | US | disclosed |
| US-20070142428-A1 | Isoquinoline-3-carboxylic acid amides and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2007-06-21 | — | — | US | disclosed |
| EP-1603883-A2 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-12-14 | — | — | EP | disclosed |
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-30 | — | — | US | disclosed |
| WO-2004069792-A2 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (US) | 2004-08-19 | — | — | WO | disclosed |
| EP-0394553-B1 | Use of fluorine containing pyridone carboxylic acid derivatives for preparing a medicament for the treatment of HIV infections | DAIICHI SEIYAKU CO (JP) | 1995-06-21 | — | — | EP | disclosed |
| EP-0470252-A1 | ANTI-HIV DRUG | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1992-02-12 | — | — | EP | disclosed |
| EP-0394553-A2 | Use of fluorine containing pyridone carboxylic acid derivatives for preparing a medicament for the treatment of HIV infections | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1990-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227774-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX6, P2RX2 | MGAM 4871/4885HCAR2 433/4885EGLN1 1270/4885 |
| US-11339169-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX6, P2RX2 | MGAM 4871/4885HCAR2 433/4885EGLN1 1270/4885 |
| US-20200190096-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX6, P2RX2 | MGAM 4871/4885HCAR2 433/4885EGLN1 1270/4885 |
| US-12077543-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX6, P2RX2 | MGAM 4871/4885HCAR2 433/4885EGLN1 1270/4885 |
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | TRPV1, OPRL1, TRPV2 | MGAM 4767/4885HCAR2 32/4885EGLN1 1780/4885 |
| US-20240391925-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX6, P2RX2 | MGAM 4871/4885HCAR2 433/4885EGLN1 1270/4885 |
| US-20070142428-A1 | Isoquinoline-3-carboxylic acid amides and pharmaceutical uses thereof | CHRNA7, CHRNA3, CHRNA1 | MGAM 3821/4885HCAR2 26/4885EGLN1 4811/4885 |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | TRPV1, OPRL1, TRPV2 | MGAM 4767/4885HCAR2 32/4885EGLN1 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.